Market Research Logo

Biodefense Market Size By Product (Vaccines {Anthrax, Smallpox, Botulism}, Biothreat Detection Devices {Samplers, Detectors/Triggering Devices, Identifiers, Assays And Reagents}), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France,

Biodefense Market Size By Product (Vaccines {Anthrax, Smallpox, Botulism}, Biothreat Detection Devices {Samplers, Detectors/Triggering Devices, Identifiers, Assays And Reagents}), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE), Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Biodefense Market will exceed USD 19 billion by 2024; as per a new research report.

Increasing government initiatives in developed as well as developing economies will drive the biodefense market growth during analysis period. Developing economies such as China have huge population and their economy relies on skilled human resource. Hence, government of China undertakes various decisions to protect its population from deliberate virus attacks that may weaken its economy due to loss of productivity. This will boost the demand for bio-threat detection devices and vaccines thereby, escalating the biodefense market growth in near future.

Government funding for development of superior quality vaccines for surviving bio-terrorism attack will augment the biodefense market growth. Government in developed countries encourage the biopharmaceutical and pharmaceutical firms to manufacture vaccines that help in boosting the immunity of individuals. Also, the government undertakes several initiatives that includes routine immunization against various endemic diseases such as small pox. Thus, growing government support will positively influence the industry growth. However, insufficient funding for R&D activities in under-developed economies will hamper the industry growth during the forecast period.

Bio-threat detection devices will grow at 6.6% CAGR during the analysis period. Newly developed biothreat devices are integrated with advanced technology and have the ability to provide accurate results in rapid testing. For instance, IMASS device developed by BBI detection contains coded test strips that can detect up to 8 biothreat agents. Recently developed biothreat detection devices deliver quick results that boosts its demand and triggers the segmental growth.

China biodefense market accounted for 27.8% revenue share in 2017 and is anticipated to have exponential growth during forecast timeframe. China has been a victim of huge biological warfare attacks from 1937 to 1945. Therefore, government in China is aware regarding the brutal impact of bioterrorism and undertakes several initiatives such as funding to research activities that boosts the biodefense activities. Aforementioned factor coupled with growing biotechnology sector in China will enhance the country growth.

Germany biodefense market was valued at USD 711.8 million in 2017. Government adopts certain initiatives to create awareness regarding the spread of endemic diseases due to deliberate release of microbes and viruses. Moreover, the regulatory bodies are involved in developing quality assurance program to maintain the standard of the biothreat devices that positively influences the industry growth.

Some of the eminent industry players operating in biodefense industry includes Altimmune, AISense, Emergent BioSolutions, Dynavax Technologies, SIGA Technologies, Elusys Therapeutics, Ichor Medical Systems, DynPort Vaccine Company, Cleveland BioLabs, Bavarian Nordic, Achaogen, Nanotherapeutics, Alnylam Pharmaceuticals, PathSensors and BBI Detection. Key industry players implement several strategies such as acquisition, mergers, geographic expansions and new product launch that enables them to achieve sustainable profits. Government signs contract with certain vaccine companies that also renders them with high revenue share. For instance, in April 2018, U.S. Department of Health and Human Services office is planning to purchase anthrax treatment from Elusys Therapeutics. Gaining such contracts from government will positively impact company’s growth.


Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Biodefense industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Biodefense Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Growing investments by government in R&D in North America & Europe
3.3.1.2. Favorable government initiatives in Asia Pacific and Latin America
3.3.1.3. Technological advancements in biotechnology sector in North America and Europe
3.3.2. Industry pitfalls and challenges
3.3.2.1. Low R&D funding by government in underdeveloped regions
3.4. Growth potential analysis
3.4.1. By product
3.5. Competitive landscape, 2017
3.5.1. Strategy dashboard
3.6. Porter's analysis
3.7. PESTEL analysis
Chapter 4. Biodefense Market, By Product
4.1. Key segment trends
4.2. Vaccines
4.2.1. Market size, by region, 2013-2024 (USD Million)
4.2.2. Anthrax
4.2.2.1. Market size, by region, 2013-2024 (USD Million)
4.2.3. Smallpox
4.2.3.1. Market size, by region, 2013-2024 (USD Million)
4.2.4. Botulism
4.2.4.1. Market size, by region, 2013-2024 (USD Million)
4.2.5. Others
4.2.5.1. Market size, by region, 2013-2024 (USD Million)
4.3. Biothreat detection devices
4.3.1. Market size, by region, 2013-2024 (USD Million)
4.3.2. Samplers
4.3.2.1. Market size, by region, 2013-2024 (USD Million)
4.3.3. Detectors/triggering devices
4.3.3.1. Market size, by region, 2013-2024 (USD Million)
4.3.4. Identifiers
4.3.4.1. Market size, by region, 2013-2024 (USD Million)
4.3.5. Assays and reagents
4.3.5.1. Market size, by region, 2013-2024 (USD Million)
Chapter 5. Biodefense Market, By Region
5.1. Key regional trends
5.2. North America
5.2.1. Market size, by country, 2013 - 2024 (USD Million)
5.2.2. Market size, by product, 2013 - 2024 (USD Million)
5.2.3. U.S.
5.2.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.2.4. Canada
5.2.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.3. Europe
5.3.1. Market size, by country, 2013 - 2024 (USD Million)
5.3.2. Market size, by product, 2013 - 2024 (USD Million)
5.3.3. Germany
5.3.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.4. France
5.3.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.5. UK
5.3.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.6. Italy
5.3.6.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.7. Spain
5.3.7.1. Market size, by product, 2013 - 2024 (USD Million)
5.4. Asia Pacific
5.4.1. Market size, by country, 2013 - 2024 (USD Million)
5.4.2. Market size, by product, 2013 - 2024 (USD Million)
5.4.3. China
5.4.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.4. Japan
5.4.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.5. India
5.4.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.6. Australia
5.4.6.1. Market size, by product, 2013 - 2024 (USD Million)
5.5. Latin America
5.5.1. Market size, by country, 2013 - 2024 (USD Million)
5.5.2. Market size, by product, 2013 - 2024 (USD Million)
5.5.3. Brazil
5.5.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.5.4. Mexico
5.5.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.5.5. Argentina
5.5.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.6. MEA
5.6.1. Market size, by country, 2013 - 2024 (USD Million)
5.6.2. Market size, by product, 2013 - 2024 (USD Million)
5.6.3. South Africa
5.6.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.6.4. Saudi Arabia
5.6.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.6.5. UAE
5.6.5.1. Market size, by product, 2013 - 2024 (USD Million)
Chapter 6. Company Profiles
6.1 Achaogen
6.1.1. Business overview
6.1.2. Financial data
6.1.3. Product landscape
6.1.4. Strategic outlook
6.1.5. SWOT analysis
6.2. Alnylam Pharmaceuticals
6.2.1. Business overview
6.2.2. Financial data
6.2.3. Product landscape
6.2.4. Strategic outlook
6.2.5. SWOT analysis
6.3. Altimmune
6.3.1. Business overview
6.3.2. Financial data
6.3.3. Product landscape
6.3.4. Strategic outlook
6.3.5. SWOT analysis
6.4. Alexeter Technologies, LLC
6.4.1. Business overview
6.4.2. Financial data
6.4.3. Product landscape
6.4.4. Strategic outlook
6.4.5. SWOT analysis
6.5. ANP Technologies
6.5.1. Business overview
6.5.2. Financial data
6.5.3. Product landscape
6.5.4. Strategic outlook
6.5.5. SWOT analysis
6.6. Bavarian Nordic
6.6.1. Business overview
6.6.2. Financial data
6.6.3. Product landscape
6.6.4. Strategic outlook
6.6.5. SWOT analysis
6.7. BBI Detection
6.7.1. Business overview
6.7.2. Financial data
6.7.3. Product landscape
6.7.4. Strategic outlook
6.7.5. SWOT analysis
6.8. Cleveland BioLabs, Inc.
6.8.1. Business overview
6.8.2. Financial data
6.8.3. Product landscape
6.8.4. Strategic outlook
6.8.5. SWOT analysis
6.9. DynPort Vaccine Company LLC
6.9.1. Business overview
6.9.2. Financial data
6.9.3. Product landscape
6.9.4. Strategic outlook
6.9.5. SWOT analysis
6.10. Elusys Therapeutics
6.10.1. Business overview
6.10.2. Financial data
6.10.3. Product landscape
6.10.4. Strategic outlook
6.10.5. SWOT analysis
6.11. Emergent BioSolutions
6.11.1. Business overview
6.11.2. Financial data
6.11.3. Product landscape
6.11.4. Strategic outlook
6.11.5. SWOT analysis
6.12. Ichor Medical Systems, Inc.
6.12.1. Business overview
6.12.2. Financial data
6.12.3. Product landscape
6.12.4. Strategic outlook
6.12.5. SWOT analysis
6.13. New Horizons Diagnostics
6.13.1. Business overview
6.13.2. Financial data
6.13.3. Product landscape
6.13.4. Strategic outlook
6.13.5. SWOT analysis
6.14. PathSensors
6.14.1. Business overview
6.14.2. Financial data
6.14.3. Product landscape
6.14.4. Strategic outlook
6.14.5. SWOT analysis
6.15. Research International
6.15.1. Business overview
6.15.2. Financial data
6.15.3. Product landscape
6.15.4. Strategic outlook
6.15.5. SWOT analysis
6.16. SIGA Technologies
6.16.1. Business overview
6.16.2. Financial data
6.16.3. Product landscape
6.16.4. Strategic outlook
6.16.5. SWOT analysis
Data Tables/B>
TABLE 1. Biodefense industry 360 degree synopsis, 2013 - 2024
TABLE 2. Biodefense market, 2013-2024 (USD Mn)
TABLE 3. Biodefense market, by product, 2013-2024 (USD Mn)
TABLE 4. Biodefense market, by application, 2013-2024 (USD Mn)
TABLE 5. Biodefense market, by end-user 2013-2024 (USD Mn)
TABLE 6. Biodefense market, by region, 2013-2024 (USD Mn)
TABLE 7. Industry impact forces
TABLE 8. Vaccines market size, by region, 2013-2024 (USD Mn)
TABLE 9. Anthrax market size, by region, 2013-2024 (USD Mn)
TABLE 10. Smallpox market size, by region, 2013-2024 (USD Mn)
TABLE 11. Botulism market size, by region, 2013-2024 (USD Mn)
TABLE 12. Others market size, by region, 2013-2024 (USD Mn)
TABLE 13. Biothreat detection devices market size, by region, 2013-2024 (USD Mn)
TABLE 14. Samplers market size, by region, 2013-2024 (USD Mn)
TABLE 15. Detectors/triggering devices market size, by region, 2013-2024 (USD Mn)
TABLE 16. Identifiers market size, by region, 2013-2024 (USD Mn)
TABLE 17. Assays and reagents market size, by region, 2013-2024 (USD Mn)
TABLE 18. North America biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 19. North America biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 20. U.S. biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 21. Canada biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 22. Europe biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 23. Europe biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 24. Germany biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 25. UK biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 26. France biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 27. Spain biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 28. Italy biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 29. Asia Pacific biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 30. Asia Pacific biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 31. Japan biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 32. China biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 33. India biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 34. Australia biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 35. Latin America biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 36. Latin America biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 37. Brazil biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 38. Mexico biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 39. Argentina biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 40. MEA biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 41. MEA biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 42. South Africa biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 43. Saudi Arabia biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 44. UAE biodefense market size, by product, 2013-2024 (USD Mn)
Charts & Figures
FIG 1. Industry segmentation
FIG 2. Global biodefense market, 2013 - 2024 (USD Mn)
FIG 3. Growth potential analysis, by product
FIG 4. Porter's analysis
FIG 5. Strategy dashboard
FIG 6. PESTEL analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report